Q1 Earnings Estimate for AVBP Issued By B. Riley

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Analysts at B. Riley issued their Q1 2025 EPS estimates for ArriVent BioPharma in a research note issued to investors on Wednesday, March 19th. B. Riley analyst K. Patel anticipates that the company will post earnings per share of ($0.70) for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. B. Riley also issued estimates for ArriVent BioPharma’s Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.86) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.30) EPS, FY2026 earnings at ($4.64) EPS, FY2027 earnings at ($3.52) EPS, FY2028 earnings at ($1.75) EPS and FY2029 earnings at $0.40 EPS.

ArriVent BioPharma (NASDAQ:AVBP) last posted its earnings results on Monday, March 3rd. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.18.

Other analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $39.00 price target on shares of ArriVent BioPharma in a report on Friday, March 7th. Guggenheim began coverage on shares of ArriVent BioPharma in a report on Monday, March 10th. They issued a “buy” rating and a $45.00 target price on the stock. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, ArriVent BioPharma presently has a consensus rating of “Buy” and a consensus target price of $39.00.

ArriVent BioPharma Stock Performance

NASDAQ AVBP opened at $20.21 on Monday. ArriVent BioPharma has a one year low of $14.35 and a one year high of $36.37. The stock has a 50-day moving average of $24.82 and a 200 day moving average of $26.68. The company has a market capitalization of $687.46 million, a price-to-earnings ratio of -7.86 and a beta of 1.00.

Institutional Trading of ArriVent BioPharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Infinitum Asset Management LLC bought a new stake in shares of ArriVent BioPharma during the 4th quarter valued at $43,794,000. Suvretta Capital Management LLC increased its position in ArriVent BioPharma by 21.7% in the fourth quarter. Suvretta Capital Management LLC now owns 2,246,000 shares of the company’s stock worth $59,833,000 after buying an additional 400,838 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of ArriVent BioPharma by 154.2% during the 3rd quarter. Geode Capital Management LLC now owns 597,165 shares of the company’s stock valued at $14,036,000 after buying an additional 362,221 shares in the last quarter. State Street Corp grew its stake in shares of ArriVent BioPharma by 210.4% during the 3rd quarter. State Street Corp now owns 476,809 shares of the company’s stock valued at $11,205,000 after acquiring an additional 323,186 shares during the period. Finally, FMR LLC increased its holdings in ArriVent BioPharma by 8.7% in the 3rd quarter. FMR LLC now owns 2,119,695 shares of the company’s stock worth $49,813,000 after acquiring an additional 169,514 shares in the last quarter. 9.48% of the stock is owned by hedge funds and other institutional investors.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.